Novo Nordisk A/S
This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥) 30 days before screening. * Treatment naïve to any glucose-lowering medication(s). Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * Current treatment or history of treatment with any medication for the indication of diabetes, or treatment wi…
Zenagamtide will be administered subcutaneously once weekly.
Placebo matched to zenagamtide will be administered subcutaneously once weekly.